Division of Infectious Diseases

Follow @UNMC_ID at #IDWEEK2018!

IDWeek is here and we want to be sure YOU know where to find us! Below is the list of faculty presentations and posters from our Division. Please come visit us at IDWeek –  We would LOVE to meet you! 

Content courtesy of Sandy Nelson and the entire UNMC ID Division. 

Tuesday, October 2
Session: The Vincent T. Andriole ID Board Review Course
Session Title: Infections in Transplant
Presenter: Andrea Zimmer, MD
Session time: 8:00 a.m. – 5:00 p.m.
Session location: W 2005-2020

Thursday October 4
Meet-the-Professor Session
Session: Are You Ready? Outbreak Response Training
Presenter: Angela Hewlett, MD
Session time: 7:15-8:15 a.m.
Session location: S 152-154

Session: Cool Findings in Bacteremia and Endocarditis
Session Time: 11:30-12:45 p.m.
Session Location: W 2002
Presentation Title: The Effect of Insurance Coverage on Appropriate Selection of Hospital Discharge Antibiotics for Staphylococcus aureus Bacteremia
Authors: Mark E. Rupp, MD, Trevor Van Schooneveld, MD, FACP et al
Presentation Number: 158

Posters 12:30-1:45pm

Session: Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record
Presentation Title: Impact of a Best Practice Alert Linking Clostridium difficile Infection Test Results to a Severity-based Treatment Order Set
Authors: Trevor Van Schooneveld, MD, FACP, Scott Bergman, PharmD, FIDSA, FCCP, BCPS et al
Presentation Number: 178

Session: Antimicrobial Stewardship: Interventions to Improve Outcomes
Presentation Title: Respiratory Viral Testing is Associated with Lower Frequency of Antibiotic Prescribing for Acute Upper Respiratory Infections at a Large Ambulatory Cancer Center
Authors: Erica Stohs, MD, MPH et al
Presentation Number: 206

Session: Bone and joint Infections
Presentation Title: Effect of Previous Antibiotic Exposure on the Yield of Bone Biopsy Culture in Patients with Osteomyelitis
Authors: Paul Fey PhD, Angela Hewlett MD, Mark Rupp MD et al
Presentation Number: 291

Session: Fungal Disease: Management and Outcomes
Presentation Title: Breakthrough Pneumocystis jirovecii Pneumonia among Cancer Patients: Opportunity for Antimicrobial Stewardship?
Authors: Erica Stohs, MD, MPH et al
Presentation Number: 402

Session: Microbiome and Beyond
Presentation Title: Vancomycin is Frequently Administered to Hematopoietic Cell Transplant Recipients without a Provider Documented Indication and Correlates with Microbiome Disruption and Adverse Events.
Authors: Erica Stohs, MD et al
Presentation Number: 616

Friday, October 5

Posters 12:30-1:45pm

Session: Bacteremia and Endocarditis
Presentation Title: Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever AND Neutropenia (FN): Predictors for Morbidity and Mortality
Authors: Alison G. Freifeld, MD, Andrea Zimmer, MD, et al
Presentation Number: 1016

Session: Diarrhea Diagnostic Dilemmas
Presentation Title: The Value of Hardwiring Diagnostic Stewardship in the Electronic Health Record: Electronic Ordering Restrictions for PCR-Based Rapid Diagnostic Testing of Diarrheal Illnesses
Authors: Jasmine R Marcelin MD, Caitlin N. Murphy PhD, Paul D. Fey PhD, Trevor C. Van Schooneveld MD (et. al)
Presentation Number: 1095

Session: Healthcare Epidemiology: Non-acute Care Settings
Presentation Title: Infection Control Risk Mitigation and Implementation of Best Practice Recommendations in Long-term Care Facilities
Authors:  Mark E. Rupp, MD,  Muhammad Salman Ashraf, MBBS et al
Presentation Number: 1236

Session: Healthcare Epidemiology: Non-acute Care Settings
Presentation Title: Frequently Identified Infection Control Gaps in Outpatient Hemodialysis Centers
Authors: Mark E. Rupp, MD,  Muhammad Salman Ashraf, MBBS et al
Presentation Number: 1239

Session: HIV: Diagnosis and Screening
Presentation Title: Routine opt-out HIV screening and detection of HIV infection among emergency department patients
Authors: Nada Fadul, MD et al
Presentation Number: 1273

Session: HIV: Prevention
Presentation Title: Knowledge, Attitudes and Barriers of Pre-exposure Prophylaxis for HIV Infection Among Resident Physicians in Rural, Eastern North Carolina
Authors: Nada Fadul, MD et al
Presentation Number: 1289

Session: HIV: Prevention
Presentation Title: Acceptability and Feasibility of a Pharmacist-led Pre-exposure Prophylaxis Program in the Midwestern United States
Authors: Sara H. Bares, Joshua P. Havens, Kimberly K. Scarsi, Susan Swindells et al
Presentation Number: 1294

Session: Medical Education
Presentation Title: Antibiotic Prescribing Knowledge: A Brief Survey of Providers and Staff at an Ambulatory Cancer Center during Antibiotic Awareness Week 2017
Authors: Erica Stohs, MD, MPH et al
Presentation Number: 1302

Session: Respiratory Infections: Miscellaneous
Presentation Title: Impact of a Guidance Document, Order Set Changes and Physician Education on Antibiotic Prescribing in Acute Exacerbation of COPD
Authors: Scott Bergman, Trevor Van Schooneveld et al
Presentation Number: 1480

Session:Viruses and Bacteria in Immunocompromised Patients
Presentation Title: Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever AND Neutropenia (FN): Correlation between Initial Empiric Antibiotic Regimen Correlation and Susceptibility Patterns
Authors: Andrea Zimmer, MD, Alison G. Freifeld, MD et al
Presentation Number: 1585

Saturday October 6
Session: Febrile Neutropenia
Session Title: Infections in Immunocompromised Hosts
Presenter: Alison Freifeld, MD
Session time: 10:30-11:45 a.m.
Session location: S 214-216

Posters 12:30-1:45 p.m.

Session: HIV: Sexually Transmitted Infections
Presentation Title: Assessment of Anal Papanicolaou Smear Screening and Follow-up Rates in Eastern North Carolina for HIV-Positive Patients who are Men who have Sex with Men
Authors: Nada Fadul, MD et al
Presentation Number: 2274

Session: Antimicrobial Stewardship: Non-hospital Settings
Presentation Title: Comparison of Antibiotic Use in Post-Acute and Long-Term Care Facilities Based on Proportion of Short Stay Residents Using a Long-Term Care Pharmacy Database
Authors: Philip Chung, PharmD, MS, BCPS, Scott Bergman, PharmD, FIDSA, FCCP, BCPS, Mark E. Rupp, MD, Trevor Vanschooneveld, MD,  Muhammad Salman Ashraf, MBBS et al
Presentation Number: 1837

Session: Antimicrobial Stewardship: Non-hospital Settings
Presentation Title: Digging Deeper: A Closer Look at Core Elements of Antibiotic Stewardship for Long-Term Care Facilities
Authors: Scott Bergman, PharmD, FIDSA, FCCP, BCPS, Philip Chung, PharmD, MS, BCPS, Mark E. Rupp, MD, Trevor Vanschooneveld, MD, Muhammad Salman Ashraf, MBBS et al
Presentation Number: 1838

Session: 222. Antimicrobial Stewardship: Potpourri
Presentation Title: Adherence to Practice Guidelines for Treating Diabetic Foot
Infections: An Opportunity for Syndromic Stewardship
Authors: McCreery R, Bergman SJ, Van Schooneveld TC
Presentation Number: 1874

Session: Healthcare Epidemiology: Device-associated HAIs
Presentation Title: Evaluation of a Midline Catheter Program and Effect on Central Line Associated Blood Stream Infections
Authors: Richard Hankins, MD; Mark Rupp, MD, Kelly Cawcutt, MD, MS et al
Presentation Number: 2096

Find us on Twitter @UNMC_ID; #UNMCID #IDWEEK2018

ID Pharmacist Scott Bergman (@bergmanscott) and our ID faculty #tweeterIDians Drs. Jasmine Marcelin (@DrJRMarcelin), Kelly Cawcutt (@KellyCawcuttMD), Nada Fadul (@fadul_nada), Salman Ashraf (@M_Salman_Ashraf), Erica Stohs @EStohs will be tweeting from the conference, so join us in the conversation!


 

Intensive Infection Control experience for UNMC ID Fellows

The Nebraska Medicine Infection Control and Epidemiology Department (IC&E) is well recognized for excellence. The department is staffed by 5 full-time Infection Preventionists (IP), a data analyst, and a staff assistant; Terry Michaels, manages the department. Dr. Rupp serves as the Medical Director and is assisted by Drs. Ashraf, Cawcutt, Marcelin, and VanSchooneveld as Associate Directors.

During the first 2 years of ID Fellowship, UMMC ID fellows have terrific opportunities to learn about infection prevention and the hospital infection control program. Each fellow has a month-long elective in infection control – during that month of intense study, they learn the nuts and bolts of hospital infection control. Working alongside experienced IPs and medical directors, ID fellows have hands on observation of infection surveillance, healthcare associated infection prevention efforts, and outbreak investigation.

During the month rotation a small special project is also conducted and a specialized curriculum/lecture series is conducted. ID fellows are exposed to the infection control literature during a monthly infection control journal club in which they take turns critiquing recent publications along with IPs and faculty. The infection control experience is capped off by attendance of the SHEA/CDC basic course in Hospital Epidemiology. For the ID fellow interested in infection control as a career, opportunity for a third year of Fellowship directed toward specialized training in infection control and hospital epidemiology is encouraged.

Additional opportunities for experience and research in infection control is afforded through the CDC/Nebraska HHS-funded Infection Control Assessment and Promotion Program (ICAP) that is charged with improving infection control practices in health care settings (long-term care, critical access hospitals, acute care, dialysis units, ambulatory surgical centers, etc.) across the state of Nebraska. Learn more about the Nebraska ICAP directed by Dr. Salman Ashraf at https://icap.nebraskamed.com/

To learn more about individual infectious disease faculty working in infection control in the recent projects and publications, see the ID division website at https://www.unmc.edu/intmed/divisions/id/index.html

Content provided by Dr. Mark Rupp MD, Division Chief and Medical Director of Infection Control and Epidemiology

Allergy Emancipation

The following was originally posted to the Controversies in Hospital Infection Prevention Blog on 9/24/18 by Dr. Marcelin.

September 28, 2018 marks 90 years since Sir Alexander Fleming discovered penicillin as an effective antimicrobial which would soon save millions of lives. He warned soon afterwards that unless we used penicillin judiciously, we would see antibiotic resistance, and he was right. With decades of inappropriate antibiotic prescribing, we have dug ourselves a deep hole of antimicrobial resistance, and inaccurate penicillin allergies is but one shovel used to put us in this mess. How? Simple If/And/Then construct: IF unverified penicillin allergies lead to unnecessary/inappropriate use of broad-spectrum antibiotics which contributes to antimicrobial resistance, AND antimicrobial resistance is a public health problem, THEN unverified penicillin allergies are a public health problem.

In a single day on hospital service the Infectious Diseases consult team encountered a few patients with beta lactam allergies: one had developed significant angioedema in the last year with amoxicillin; another had developed a questionable rash on nafcillin therapy; a third recalled his mother telling him that he turned green after receiving oral penicillin as a child. Our approach: in the first case we avoided penicillin; in the second, we recommended a cephalosporin graded challenge which the patient tolerated; in the third, after detailed history we gave the patient full dose amoxicillin-clavulanate, he tolerated it well and he was able to discharge without IV antibiotics. These are fantastic cases for teaching purposes, but additionally, how exhilarating it is to liberate a patient from an irrelevant penicillin “allergy” and give them appropriate treatment upfront!

Penicillin allergies are frequently documented drug allergies in the hospital setting, with 10% of Americans reporting a penicillin allergy.  Some penicillin allergies are real. However, most penicillin allergies are either inaccurate or inconsequential, with only 1% of Americans actually demonstrating true allergy upon testing. Furthermore, most patients with true penicillin allergies lose hypersensitivity over time, and by 10 years after the event, 80% of patients are no longer penicillin allergic. Can you imagine if all potential food allergies were treated the same as penicillin allergies? People wouldn’t eat at all! Most people, if they have what they think might be a reaction to a food they like, might either try the food again or get tested to know for certain they cannot eat that food. But 50 years ago, if they had a rash that coincided with penicillin administration, it would never occur to them to try it again.

Once a penicillin allergy is listed in a patient’s record, they are more likely to receive inappropriate broad-spectrum antibiotics – a practice that can be both costly and have worse clinical outcomes.  Patients with methicillin-susceptible Staphylococcus aureus bacteremia treated with vancomycin instead of a beta-lactam have higher mortality rates than those receiving appropriate beta-lactam therapy. Patients undergoing surgery who receive alternative antibiotics for preoperative infection prophylaxis (due to reported penicillin allergies) have a 50% higher risk of developing a surgical site infection than those who appropriately receive beta lactam prophylaxis.

The Infectious Disease Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA) recommend that patients with reported beta lactam allergy should undergo beta lactam allergy skin testing. Allergy verification and penicillin allergy skin-testing are becoming more recognized components of antimicrobial stewardship and de-labelling allergies can have significantly improved patient outcomes.  Following a simple algorithm can help to easily identify patients suitable for skin testing and could avoid almost 3 weeks hospitalization and 1000 days of second-line antibiotics. However in some situations or in low-resource settings, it may not be practical to perform skin testing on everyone who reports a penicillin allergy. In a previous blog post about beta-lactam skin testing I mused about whether better allergy histories are more bang for the buck, since a structured allergy history can potentially decrease inappropriate 2nd line antibiotic use by 26%.

There’s an age-old joke that if a team wants a detailed history on a patient, just consult ID. If our attention to detail is already expected, shouldn’t we feel empowered to take that allergy history and de-label the penicillin allergy?  Inpatient allergy consultations are difficult to coordinate when those divisions may be understaffed and allergists are busy with outpatient practices.  So how can we capitalize on their expertise when they can’t see the patient in the hospital? Simple: partner with them to create guidance for practice, utilize ordersets for allergy de-labelling and facilitate outpatient allergy evaluations after discharge.

In honor of Sir Alexander Fleming and National Penicillin Allergy Day, let us pledge to emancipate our patients from the fake allergies. Go on, get that detailed history! Get some penicillin skin testing! Do that graded challenge! Give that first line beta-lactam antibiotic! But for goodness’ sake when you do, please DELETE the allergy from the health record so that the ordeal does not have to be repeated!

UNMC ID Division Accolades!

Our Faculty at University of Nebraska Medical Center Division of Infectious Diseases have worked hard to maintain a strong academic presence at UNMC. We are a growing division, filled with faculty at all stages of their careers, and their collective academic prowess has our division leading the pack.  We are proud of our faculty and would like to share some of their accomplishments with our followers.

Dr. Angela Hewlett has been elected to the Executive Board of the Musculoskeletal Infection Society and will serve as MSIS President in 2020. She was recently an invited delegate at the International Consensus Meeting on Periprosthetic Joint Infection in Philadelphia, where experts in orthopedic infections from around the world (over 80 countries were represented) came together to develop a document based on the available scientific evidence and consensus when evidence is lacking, that can be used to improve the care of patients with musculoskeletal infections. Dr. Hewlett will be an invited speaker at #IDWeek2018 at the Meet the Professor Session on outbreak preparedness. She also published  the book,  Bioemergency Planning: A Guide for Healthcare Facilities.

Dr. Jasmine Marcelin was awarded the SHEA Race Against Resistance Scholarship, funding provided for a new Antimicrobial Stewardship clincian to learn more about the field. Dr. Marcelin partnered with Physicians Weekly to co-moderate two twitter chats on Minorities in medicine, and was recently featured on the cover of the July issue of Helio Infectious Diseases News in an article discussing Women in Infectious Diseases.

Dr. Susan Swindells was awarded the Department of Medicine Faculty Clinical and Educational Mentoring Award.

Dr. Trevor Van Schooneveld was recently named UNMC College of Medicine Resident Program Director of the Month in September (ID Fellowship Program Director)

CRE or not CRE: A Question of Risky Business and Notes from the Field

The following was originally posted by Dr. Marcelin to the August 2018 SHEA Journal Club 

Carbapenem-resistant Enterobacteriaceae (CRE) are not as prevalent in the United States as they are in the Eastern Hemisphere; however travel within our global village means creates opportunity for movement of these organisms to our region.  The following is a review of two studies on risk predictors for CRE and three “Notes from the field” investigations from the CDC.

 The Rapid Prediction of Carbapenem Resistance in Patients With Klebsiella pneumoniae Bacteremia Using Electronic Medical Record Data. Timothy Sullivan et al.   Open Forum Infectious Diseases, Volume 5, Issue 5, 1 May 2018

In this study, the authors created a model to predict the likelihood of carbapenem resistance (as defined by imipenem MIC ≥2μg/mL) in Klebsiella pneumoniae bacteremia. 613 individual cases of K. pneumoniae bacteremia occurred over a 4 year period, with a 10% imipenem-resistance rate. Logistic regression was used for the initial model development, which was subsequently re-validated using additional statistical methods.  The model included the following; colonization with imipenem-resistant Klebsiella pneumoniae, hospital location (ICU/med-surg vs low-risk units), age (>60yrs), total oral or intravenous antibiotic days of therapy (in the past 2 years) and inpatient days (in the past 5 years). The model correctly predicted imipenem resistance in 73% of cases, with a specificity of 59%; positive predictive value of 16% and negative predictive value of 95%. All culture data present in the EMR were available to the model, eliminating manual searches when making decisions about empiric therapy. The negative predictive value is high, but lack of generalizability could limit the clinical utility.

Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms Patricia Simmer et. al  Open Forum Infectious Diseases, Volume 5, Issue 5, 1 May 2018

In this brief report, authors identified risk factors for having a CP-CRE (as compared to non-CP-CRE). Their retrospective, single-institution cohort included 96 hospitalized individuals who had CRE over a one-year period, with an incidence of CRE that year of 4%. CP-CRE isolates (predominantly K. pneumoniae) were identified in 47% of the patients. They found that CP-CRE isolates were more commonly identified in patients with recent international healthcare exposure within six months (27% vs 2%; odds ratio [OR], 18.18; 95% confidence interval [CI], 2.26–46.53); and patients who were recently transferred from a post-acute care facility (31% vs 12%; OR, 3.39; 95% CI, 1.17–9.78). Considering the prevalence of CP-CRE in regions outside the United States, should we be more intentional about asking travel history when patients are being admitted to the hospital?

The following snippets are Notes from the Field published in MMWR with new information about CRE organisms:

Verona Integron-Encoded Metallo-Beta-Lactamase–Producing Pseudomonas aeruginosa Outbreak in a Long-Term Acute Care Hospital — Orange County, Florida, 2017/MMWR Danielle Rankin, MPH et. al

The first VIM-producing Pseudomonas aeruginosa in Florida was detected in an outbreak of colonized patients at a long-term acute care hospital in Orange County. One patient was first identified in July 2017, followed by six additional patients identified in the subsequent months at the same facility. Only 2 isolates were closely related.

Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Less Common Enterobacteriaceae Genera — United States, 2014–2017/MMWR Maroya S. Walters, PhD et. al

CRE Surveillance by the Minnesota Department of Health revealed 20 CP-CRE from less common Enterobacteriaceae genera (i.e. not Klebsiella spp., Enterobacter spp. or E. coli). 7 IMP-producing Providencia rettgeri and 6 KPC-producing Citrobacter freundii predominated. Most patients with these isolates were currently hospitalized; two were previously hospitalized internationally in the last year.

Notes from the Field: Domestically Acquired Verona Integron-Mediated Metallo-β-Lactamase-Producing Enterobacteriaceae — Indiana, 2016–2017/MMWR DJ Shannon, MPH et. al

There is a question of possible regional emergence of VIM-producing CRE, with 7 patients & 9 isolates reported in Indiana between 2016-2017. One patient had three different VIM-CRE organisms isolated; all patients had prior overnight local hospitalizations and none had prior international travel within the past 6 months.


 

What’s all the buzz about West Nile Virus?

This summer, we have seen several cases of West Nile infection, prompting many questions related to the infection.

So, what’s all the buzz about West Nile? Drs. Jasmine Marcelin and Kelly Cawcutt compiled some answers to Frequently Asked Questions about West Nile.

What is West Nile Virus?  West Nile Virus is spread via mosquito bites.  Mosquitos get the virus by biting infected birds.  In North America, the virus causes disease seasonally from summer through fall, with peak infections occurring in August and September.  

Where can you get it? West Nile cases have been reported in all of the continental US states in the past, and most thus far in 2018. This year, as of CDC’s September 4 report, the leading states with cases of West Nile were North Dakota, Nebraska and South Dakota, respectively.

Who gets it? Anyone can get West Nile Virus. Besides mosquito bites, it has been spread through blood transfusions, organ donation, vertically from mother to fetus and via breast milk. Patients over age 60 are higher risk for developing infection, including serious complications.

What are the symptoms/signs of West Nile Virus infections? Most patients will not develop symptoms of infection, with only about 20% of patients falling ill. Symptomatic infection may include fever, muscle aches, headache, weakness or other nonspecific symptoms of a viral illness. According to the CDC, approximately 1 in 150 patients will develop severe, potentially fatal, infections from West Nile Virus.

Are we seeing more cases than usual this year? West Nile Virus infections vary year-to-year, but yes, there are more confirmed cases in Douglas County this year compared to last year (7 confirmed cases in 2017). In Nebraska, we already have seen more cases thus far than the entire season last year (79 cases and 4 deaths already compared to 68 cases and 2 deaths last year), but the season is not over.  Over the past several years, there are many seasons with much higher rates of infection in the state.

Is there more neuroinvasive disease than in the past? Neuroinvasive disease (e.g., meningitis, encephalitis, or acute flaccid paralysis) occurred in about 46% of West Nile Virus infections over the past 18 years of surveillance. In the state of Nebraska, 42of the 79 cases of West Nile Virus infections this year have been classified as neuroinvasive. Nationally, of the 231 cases of West Nile Virus infections reported nationally to the CDC to date, 55% have been neuroinvasive cases. However, we are just at the peak of the season and will likely see more cases that are not neuroinvasive as the season progresses.

How do I test for it? Should I re-test? In general, diagnosis of West Nile Virus requires testing blood for antibodies to the virus. IgM antibodies present indicate a current or recent infection. If a person has neurologic symptoms (concerning for neuroinvasive disease), lumbar puncture is recommended with testing of the cerebrospinal fluid for West Nile IgM. If the initial IgM test is negative but suspicion for West Nile Virus is high, the antibody test should be repeated in 10 days (Convalescent testing), particularly if symptoms persist.

What is the treatment? The best treatment is time.There is no specific medication to treat infections due to West Nile Virus. Patients with this infection usually require symptomatic management, like fluids, supplemental oxygen, etc. Other treatments like antivirals, intravenous immunoglobulin (IVIG), or plasma exchange have not been proven to be beneficial.

Can it be prevented? There is no vaccine for West Nile Virus.  You can prevent West Nile infection by preventing mosquito bites. Use long sleeves, pants and insect repellents such as DEET or Picardin. Check out the EPA repellent information to help choose the best option here: https://www.epa.gov/insect-repellents/find-repellent-right-you

References:
https://www.cdc.gov/westnile/index.html 
https://www.cdc.gov/westnile/statsmaps/preliminarymapsdata2018/disease-cases-state-2018.html


 

Are we ready for an outbreak?

It has been said that ‘an outbreak anywhere is a risk everywhere’.   At any given time, there are multiple concurrent outbreaks of highly hazardous communicable diseases, and the ease of global travel creates the risk of rapid spread of diseases around the world.  The Nebraska Biocontainment Unit (NBU) closely and continuously monitors these outbreaks, since the NBU could be called upon to care for patients who are infected with diseases like Ebola and Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

The current outbreak of Ebola is located in the Northeast part of the Democratic Republic of Congo (DRC), close to the borders of Rwanda and Uganda. This area is a known conflict zone, with significant cross-border movement.  As of September 2, there were 118 people with confirmed or suspected Ebola virus disease, and 77 deaths.  Contact tracing and vaccination efforts are underway, and experimental therapeutic agents have been administered in an attempt to control the outbreak.   This is the 10th Ebola outbreak in the DRC.

There is also an ongoing outbreak of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Arabian Peninsula.  Although most cases have occurred in Saudi Arabia, multiple other countries have been affected.  Imported cases have also occurred, including a single traveler arriving in South Korea that resulted in 186 secondary cases.  Most recently, an ill traveler presented for care in the United Kingdom and was found to be infected with MERS-CoV.

These outbreaks are only a small sample of the infectious diseases that are occurring in the world today.  The Nebraska Biocontainment Unit maintains the highest degree of preparedness, including ongoing staff training, drills and exercises.  NBU team members are continually leading and participating in the training and education of other healthcare centers in the United States and around the world.  If we receive the call to care for patients with highly hazardous communicable diseases, we are ready.

Content courtesy Dr. Angela Hewlett, Director of the Nebraska Biocontainment Unit

New Faculty Spotlight – Daniel Cramer, MSN, APRN, FNP-C

We are thrilled to have another member of our UNMC ID team. Read on to learn a little more about Daniel Cramer, who is joining our new Orthopedic Infectious Diseases team.

Why did you choose to stay at UNMC?

UNMC is home for me!  I completed my undergraduate degree here, as well as my graduate degree.  I previously was a staff nurse at Nebraska Medicine for about 5 years and the connections and friendships I have formed at UNMC and Nebraska Medicine are what keeps me here.  Beyond the connections and friendships, the commitment to extraordinary patient care and cutting-edge medicine is also a huge draw for me as well.

What makes you excited about working in ID?

I have always had a passion for infectious disease medicine from the start of my educational journey!  My first undergraduate degree was to be microbiology at Nebraska Wesleyan before I decided to pursue a career as a nurse practitioner.  I knew my dream job was to be in infectious disease when I did a two-month rotation at the specialty care clinic and I told myself after that rotation that I would steer my career towards infectious disease!  I love that having a career in infectious disease allows me to participate in cutting edge research, as well as providing excellent patient centered care.

Tell us something about yourself that is unrelated to medicine?

Something about myself that is unrelated to medicine is that I absolutely love supporting the arts in Omaha!  I am a member of the Young Arts Patrons, as well as a                                                     new season ticket holder to the Omaha symphony!


 

UNMC ID’s Dr. Diana Florescu wins DANCE FOR A CHANCE

Back in May, we were thrilled to announce that Dr. Florescu was participating in YES Dance for a Chance

Dance for a Chance raises awareness and money for Youth Emergency Services (YES) and the homeless youth of Omaha. There are hundreds of homeless youth in Omaha. Some of them have been emotionally, physically, or sexually abused, making it unsafe for them to return home, while others are facing health, mental health, or substance abuse issues. At the end of the competition, there will be 3 winners – the team with the most votes (money), the team with the best dance, and most importantly, the homeless youth of Omaha. More information can be found here.

Dr. Florescu awed the crowd and won best dance,all while raising over $6000 for YES! She would like to also extend thanks to her dance partner, Derek Pasqualetto from Vintage Ballroom as her dance instructor, partner and for his graciousness in volunteering his time for this fantastic cause.

We are so proud of Dr. Florescu for sharing her talent of dance with the community for such a great cause. Thank you to all who supported Dr. Florescu, YES, Omaha and all endeavors to continue to provide a safe, healthy and welcoming community for everyone in the Omaha area and beyond!

 

 

 


 

Clinical Pearls From Case Conference: Focus on CNS Infections

At Case Conference on August 16, Drs. Hankins and McCreery presented excellent cases of viral CNS infections combined with a great review of pertinent literature.  Here are the key clinical pearls from their presentations.

Dr. McCreery on viral and bacterial meningitis:

  1. Empiric dexamethasone appears to be beneficial in S. Pneumoniae and H. Influenza meningitis but should be stopped if found to have viral meningitis or meningitis caused by other bacteria.
  2. The addition of an aminoglycoside in the treatment of Listeria bacteremia and neurolisteriosis was associated with improved mortality in the MONALISA study – France (OR 0.60 (0.38-0.94) p 0.024) n = 679.  When neurolisteriosis was examined (n=-252 cases), some with bacteremia and some without, the addition of an aminoglycoside was not reported to have been associated with improved outcomes.
  3. Mild HSV-2 meningitis likely does not require treatment, however there may be some benefit among immunocompromised patients related to preventing neurologic sequelea.
  4. Suppressive valacyclovir after HSV-2 meningitis was associated with increased recurrence after cessation.
  5. Data is lacking regarding the utility of suppressive valacyclovir therapy in the treatment of non-genital HSV-2 infection during pregnancy

Randy McCreery MD, UNMC 1st Year ID fellow.

Dr. Hankins on Influenza Encephalitis:

  1. Diagnosis of exclusion in patients with altered level of consciousness and a positive influenza antigen or PCR.
  2. Most often occurs in 24-48 hours after febrile incident.
  3. 95% of patients with influenza encephalitis are younger than 21 years old.
  4. Associated with bilateral thalamic necrosis on MRI.
  5. Guidelines suggest that oseltamivir may be beneficial.  Other studies suggest that methylprednisolone pulse therapy may be beneficial.

Richard Hankins, MD
2nd Year ID Fellow

 

 

 

 

 

 

 


 

 

Subscribe